Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2014

View Archived Issues

Ebola virus evades the STAT1-mediated immune response

Novel EZH2 inhibitors for diffuse large B-cell lymphoma identified at Pfizer

Isis Pharmaceuticals designs new huntingtin ASOs

Novartis divulges new anti-IL-17A MAbs

German researchers disclose new MAGE A1-recognizing constructs

Discovery of antibacterial compounds with promising activity against Gram-positive pathogens

Novel LXR agonists for the treatment of lipoprotein disorders

INSERM reports new polypeptides for mitochondrial disorders

Swedish group patents new deuterated catecholamine derivatives

DMC recommends initiation of Ruthigen's phase I/II study of RUT-58-60

Patrys plans phase Ib/II study of PAT-SM6 with carfilzomib in multiple myeloma

Pfizer and Merck & Co. to evaluate combination of pembrolizumab and crizotinib

Alkermes initiates phase I trial of the opioid modulator ALKS-7106

NIH supports Sorrento Therapeutics' development of immunotherapy for IPF

BeiGene moves BTK inhibitor BGB-3111 into the clinic

FDA approves Promacta for severe aplastic anemia

Identification of TLR agonists as novel markers for SSc

Innate Pharma's IPH-4102 receives E.U. orphan drug status for cutaneous T-cell lymphoma

EMA accepts for review Cubist's MAA for ceftolozane/tazobactam

Vivolux plans phase I study of VLX-600 for refractory advanced solid tumors

Empagliflozin launched in the U.S. for type 2 diabetes

Adocia launches phase III study of BioChaperone PDGF-BB in diabetic foot ulcers

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...